List of Excipients in Branded Drug FUZEON

FUZEON Excipient Strategy and Commercial Opportunities for Enfuvirtide

Last updated: August 13, 2026

Fuzeon (enfuvirtide) is a lyophilized, twice-daily subcutaneous peptide injection whose commercial limitations arise from administration burden, reconstitution, cold-chain handling, and manufacturing complexity rather than from an active pharmaceutical ingredient shortage. Its formulation uses a narrow excipient system: mannitol as a bulking agent and stabilizer, sodium carbonate as a buffer, and hydrochloric acid or sodium hydroxide for pH adjustment. The strongest commercial opportunities are in ready-to-use delivery, lower-burden reconstitution, contract manufacturing, regional supply, and reformulation of the 36-amino-acid peptide.

What is Fuzeon and how is it formulated?

Fuzeon contains enfuvirtide, also known as T-20, a 36-amino-acid HIV-1 fusion inhibitor. The product is administered subcutaneously at 90 mg twice daily in combination with other antiretroviral agents. It was developed by Trimeris and marketed by Roche and Genentech.

Each vial contains 108 mg of enfuvirtide as a sterile lyophilized powder. The labeled dose is prepared by reconstituting the vial with 1.1 mL of Sterile Water for Injection, producing approximately 1 mL for administration at a concentration of 90 mg/mL.[1]

Product characteristic	Fuzeon specification
Active ingredient	Enfuvirtide
Drug class	HIV-1 fusion inhibitor
Dosage form	Lyophilized powder for injection
Route	Subcutaneous
Dose	90 mg twice daily
Vial content	108 mg enfuvirtide
Reconstitution	1.1 mL Sterile Water for Injection
Administered volume	Approximately 1 mL
Primary excipients	Mannitol, sodium carbonate
pH modifiers	Hydrochloric acid and sodium hydroxide
Original developers	Trimeris and Roche
FDA application	NDA 021481

The formulation is designed to protect a peptide during storage while allowing rapid dissolution after reconstitution. The high concentration and subcutaneous route impose constraints on viscosity, injection force, local tolerability, aggregation, and particulate control.

What excipients are used in Fuzeon?

The principal formulation excipients are mannitol and sodium carbonate. Hydrochloric acid and sodium hydroxide are used to adjust the formulation pH. Sterile Water for Injection is supplied separately as the reconstitution diluent.[1]

Mannitol

Mannitol likely performs several formulation functions:

• Provides bulk to the lyophilized cake.
• Supports cake structure during freeze-drying.
• Contributes to osmotic balance after reconstitution.
• Helps maintain a visually acceptable dried product.
• Provides a relatively established injectable excipient platform.

Mannitol is widely used in parenteral products, reducing regulatory novelty. Its limitations include potential crystallization during lyophilization, which can alter cake structure and affect peptide stability. The mannitol concentration, freezing cycle, annealing conditions, and drying parameters therefore have commercial significance even if the excipient itself is unpatented or broadly known.

Sodium carbonate

Sodium carbonate functions primarily as a buffering and alkalinity-control agent. Enfuvirtide stability depends on the product remaining within a controlled pH range. The formulation must balance peptide solubility against degradation, aggregation, and injection-site tolerability.

Sodium carbonate is less commonly associated with modern high-volume injectable products than phosphate, citrate, or histidine buffers. That may create opportunities for formulation developers to evaluate alternative buffers, but changing the buffer would trigger comparability and stability work rather than provide a simple excipient substitution.

Hydrochloric acid and sodium hydroxide

These agents adjust pH during manufacture. They are generally process excipients rather than value-driving formulation components. Their commercial relevance is linked to manufacturing control, pH reproducibility, and compatibility with the peptide and container-closure system.

Sterile Water for Injection

Sterile Water for Injection is the required diluent under the U.S. label. It is not part of the dry cake but is essential to the product's use. Any attempt to replace the diluent with a premixed liquid, bacteriostatic water, or another vehicle would represent a product change requiring separate regulatory justification.

What formulation problems create excipient opportunities for Fuzeon?

The main opportunity is reducing the burden imposed by twice-daily reconstitution and injection.

Reconstitution burden

The labeled preparation process requires the patient or caregiver to add sterile water, mix the vial, inspect the solution, and inject the dose. The process can take several minutes and must be repeated twice daily. This limits adherence and creates opportunities for:

• Pre-reconstituted liquid presentations.
• Dual-chamber syringes or cartridges.
• Auto-reconstitution devices.
• Ready-to-use prefilled syringes.
• Simplified single-use administration kits.

A ready-to-use formulation would require control of peptide stability in solution, microbial integrity, container adsorption, oxidation, aggregation, and shelf life.

Injection-site reactions

Fuzeon is associated with frequent injection-site reactions, including pain, erythema, induration, nodules, and pruritus.[1] Excipients alone may not solve this problem because the reaction can arise from the peptide, concentration, injection volume, repeated administration, local tissue exposure, and injection technique.

Potential approaches include:

• Lower-concentration formulations with larger injection volumes.
• Higher-concentration formulations with smaller injection volumes, subject to viscosity and tolerability limits.
• Alternative buffers.
• Surfactants or peptide-stabilizing excipients.
• Sustained-release depots.
• Alternative delivery routes.

Each approach would require clinical evidence because local tolerability is a central product attribute.

Peptide aggregation and adsorption

Enfuvirtide is a relatively large synthetic peptide. Peptides can adsorb to glass, elastomers, plastics, and filtration materials. They can also aggregate or undergo chemical degradation during manufacture and storage.

Commercial formulation work should examine:

• Low-binding vial and syringe materials.
• Silicone oil exposure in prefilled syringes.
• Stopper extractables and leachables.
• Protein or peptide adsorption to tubing and filters.
• Freeze-drying stress.
• Reconstituted hold time.
• Visible and subvisible particles.
• Oxidative and hydrolytic degradation.

A surfactant could reduce interfacial adsorption, but the selected material would require a clear benefit-risk justification for subcutaneous use.

What commercial opportunities exist for Fuzeon excipients?

The opportunity is stronger in integrated formulation and delivery systems than in commodity excipient supply.

Opportunity	Commercial attractiveness	Main barrier
GMP mannitol supply	Moderate	Commodity pricing and established suppliers
Sodium carbonate supply	Low to moderate	Limited differentiation
Sterile diluent supply	Moderate	Sterility and packaging economics
Lyophilization contract manufacturing	High	Peptide process capability
Prefilled syringe	High	Liquid stability and device compatibility
Dual-chamber delivery system	High	Device development and combination-product regulation
Alternative buffer formulation	Moderate	Comparability and clinical evidence
Long-acting depot	High	New formulation, pharmacokinetic and clinical program
Low-adsorption container system	Moderate to high	Extractables, leachables, and stability data
Regional generic or follow-on product	Moderate	Regulatory pathway and market size

Lyophilization and contract manufacturing

The most immediate B2B opportunity is a specialized manufacturing platform for synthetic injectable peptides. A supplier with validated capabilities in peptide purification, sterile filtration, aseptic filling, lyophilization, and analytical characterization could support a follow-on product or regional supply arrangement.

The critical capabilities include:

• High-purity peptide manufacture.
• Control of deletion sequences and related impurities.
• Low-bioburden processing.
• Sterile filtration compatibility.
• Reproducible cake formation.
• Reconstitution-time control.
• Peptide aggregation analytics.
• Container-closure integrity testing.

The formulation excipients are relatively simple. Manufacturing control is more defensible than excipient novelty.

Ready-to-use liquid formulation

A stable liquid formulation could remove the most visible use barrier. Candidate development would focus on buffer selection, pH, concentration, tonicity, surfactant use, and container material.

A successful product could be delivered in:

• A prefilled syringe.
• A single-dose cartridge.
• An autoinjector.
• A dual-chamber device that stores dry enfuvirtide separately from the diluent.

The commercial value would depend on whether the product can support a meaningful shelf life without frozen storage. A liquid product that requires refrigeration and has a short in-use period would provide limited differentiation.

Device-enabled reconstitution

A dual-chamber system may offer a lower-risk alternative to a fully liquid formulation. The dry peptide remains lyophilized until use, while the diluent is stored in an integrated chamber. Activation would mix the components immediately before injection.

This approach preserves the stability advantages of lyophilization while reducing preparation steps. The main development issues are:

• Complete and reproducible mixing.
• Dose recovery.
• Dead volume.
• Device compatibility.
• Needle safety.
• Human factors.
• Extractables and leachables.
• Combination-product regulatory requirements.

What patents protect Fuzeon and its formulation?

The core Fuzeon patent estate was built around enfuvirtide and HIV fusion-inhibitor technology. Key early U.S. patents associated with the drug and its development date from the 1990s and early 2000s. Many fundamental composition and platform patents have reached or passed their ordinary U.S. patent terms, subject to patent-term adjustment, terminal disclaimers, continuations, and jurisdiction-specific rules.

The formulation opportunity should be assessed separately from the original molecule estate. The labeled excipients, including mannitol and sodium carbonate, are established pharmaceutical materials and generally offer limited standalone exclusivity. A defensible patent position would more likely rely on:

• A specific excipient ratio.
• A defined pH range linked to improved stability.
• A particular lyophilization cycle.
• A low-adsorption container system.
• A ready-to-use liquid formulation.
• A dual-chamber device.
• A long-acting depot.
• A defined impurity profile or reconstitution-time limitation.

A patent claim directed only to the use of mannitol or sodium carbonate in an injectable peptide formulation would face substantial prior-art exposure. Commercial protection is more plausible where the formulation produces a measurable technical effect, such as longer room-temperature stability, reduced aggregation, lower injection-site reactions, or improved reconstitution performance.

What is the FDA regulatory status of Fuzeon?

Fuzeon received FDA approval in March 2003 under NDA 021481.[2] The product was approved through the conventional new-drug pathway for treatment-experienced patients with HIV-1 infection in combination with other antiretroviral agents.

The product's regulatory profile is important for follow-on development:

• Enfuvirtide is a synthetic peptide rather than a conventional small molecule.
• The dosage form is a sterile injectable.
• The reference product has a complex manufacturing process.
• The product requires reconstitution before use.
• Demonstrating pharmaceutical equivalence may not be sufficient to eliminate clinical or immunogenicity-related concerns.
• A follow-on developer may evaluate a 505(b)(2) strategy or an abbreviated pathway, depending on the reference-product and regulatory status at the time of filing.

Fuzeon does not create a biosimilar opportunity in the conventional monoclonal-antibody sense. Enfuvirtide is not a biologic of the type typically developed under the U.S. biosimilar pathway. The principal competitive route is a generic or follow-on synthetic peptide product, potentially supported by a hybrid application.

When does Fuzeon lose exclusivity and what generic-entry risks exist?

The practical exclusivity position is driven by three factors: the age of the original patent estate, FDA regulatory exclusivity, and the commercial availability of the reference product.

FDA approval occurred in 2003. Any original five-year new chemical entity exclusivity would have expired years ago, and the commercial significance of the product is now determined mainly by patent status, regulatory pathway, manufacturing feasibility, and market demand.[2,3]

Exclusivity factor	Assessment
FDA approval	March 2003
Original NCE exclusivity	Expired
Fundamental molecule patents	Generally mature or expired in the U.S., subject to family-specific review
Formulation patents	Must be assessed by claim and jurisdiction
Orange Book relevance	Product and patent listing status must be checked against current FDA records
Paragraph IV risk	Possible for an active listed patent, but commercial incentive may be limited
Biosimilar risk	Not the primary pathway
Generic or hybrid risk	Technically possible, but manufacturing and market-size barriers are material

A Paragraph IV challenge could target any unexpired listed patent covering the formulation, method of use, or drug product. The commercial decision would depend on whether the reference product remains actively marketed, whether the listing is enforceable, and whether the expected HIV salvage-therapy market can support development costs.

Which companies are positioned to challenge or replace Fuzeon?

The competitive field is more likely to consist of HIV drug developers, specialty generic companies, peptide manufacturers, and contract development and manufacturing organizations than large-volume commodity excipient suppliers.

Potential participants include:

• Specialty generic companies with sterile injectable capabilities.
• Peptide manufacturers with GMP synthetic production.
• HIV-focused companies seeking salvage-therapy products.
• Device manufacturers with dual-chamber or autoinjector platforms.
• CDMOs with lyophilized injectable capacity.
• Regional pharmaceutical companies serving markets where enfuvirtide remains clinically relevant.

No major biosimilar competition is expected because Fuzeon is not a monoclonal antibody or other conventional biologic product. Competitive displacement is more likely to come from newer antiretroviral regimens, long-acting HIV therapies, and products with lower administration frequency than from a direct excipient-matched generic.

How does Fuzeon compare with newer HIV therapies?

Fuzeon's twice-daily subcutaneous administration is commercially disadvantaged against modern oral combination therapies and long-acting injectable regimens. Its clinical role has been concentrated in heavily treatment-experienced patients with multidrug-resistant HIV, where its distinct mechanism can retain value.

Attribute	Fuzeon	Modern long-acting HIV therapy
Administration	Subcutaneous twice daily	Often monthly or every two months, depending on product
Preparation	Reconstitution required	Product-specific administration process
Injection-site burden	High	Present but less frequent
Mechanism	Fusion inhibition	Usually combination mechanisms
Patient population	Treatment-experienced or resistant HIV	Broader maintenance populations
Formulation opportunity	Ready-to-use, depot, device	Device optimization and dosing interval
Commercial risk	Small, specialized market	Larger market but stronger competition

An improved Fuzeon presentation would need to overcome both formulation friction and therapeutic substitution. Excipients can improve usability, but they cannot by themselves reverse the shift toward long-acting and more potent antiretroviral regimens.

What manufacturing and intellectual-property barriers affect commercialization?

The primary barriers are technical and economic.

Manufacturing barriers

Enfuvirtide production requires control over peptide synthesis, cleavage, purification, residual reagents, related substances, and batch consistency. The final product also requires sterile processing and lyophilization. A lower-cost excipient system does not materially reduce the cost of the active peptide or the sterile manufacturing process.

Intellectual-property barriers

New protection is more achievable for a differentiated presentation than for the original excipients. High-value claims would target:

• Improved stability at room temperature.
• A liquid formulation with defined shelf life.
• A low-pain or low-reaction formulation.
• A reconstitution device.
• A sustained-release formulation.
• A specific container and closure combination.
• A manufacturing process that improves purity or yield.

Market barriers

The patient population is specialized, and competing antiretroviral products reduce demand. A generic developer must also account for prescriber familiarity, HIV treatment guidelines, reimbursement, distribution, and the possibility that the reference product is discontinued or difficult to source.

What licensing deals could support a Fuzeon follow-on product?

A viable licensing structure would likely combine several rights rather than license an excipient alone.

Potential deal components include:

1. Enfuvirtide peptide manufacturing rights.
2. Access to historical formulation and stability data.
3. Rights to a liquid or depot formulation.
4. Device licensing for reconstitution or injection.
5. Regional commercialization rights.
6. CDMO supply commitments.
7. Patent prosecution and enforcement rights.
8. Regulatory support for a 505(b)(2) or equivalent non-U.S. application.

A formulation company with a proprietary delivery system could license the platform to a specialty pharmaceutical company, while the peptide manufacturer supplies the active ingredient under a long-term agreement. The commercial case improves if the deal targets regions where Fuzeon remains clinically used and where access to treatment-experienced HIV products is limited.

Key Takeaways

• Fuzeon uses a simple excipient system based on mannitol, sodium carbonate, pH modifiers, and Sterile Water for Injection.
• The strongest opportunity is not commodity excipient supply. It is formulation and delivery redesign.
• A ready-to-use liquid, dual-chamber device, or long-acting formulation could address reconstitution and twice-daily injection burdens.
• Fuzeon has no conventional biosimilar opportunity; competition would come from synthetic peptide generics, hybrid applications, or improved HIV therapies.
• Fundamental Fuzeon patent protection is mature, while new commercial protection would need to focus on formulation, device, manufacturing, or dosing improvements.
• The main barriers are peptide manufacturing, sterile lyophilization, stability, injection-site tolerability, limited market size, and therapeutic substitution.
• A licensing deal would be most credible if it combined peptide supply, formulation technology, device rights, and regional commercialization.

FAQs

Can mannitol in Fuzeon be replaced with another bulking agent?

Yes, but the change would require comparative stability, reconstitution, cake-structure, particulate, and clinical or regulatory justification. Mannitol has a strong injectable precedent, so replacement must provide a measurable advantage.

Could Fuzeon be converted into a prefilled syringe?

Potentially. The principal challenges are liquid-state peptide stability, aggregation, adsorption to syringe components, container closure integrity, shelf life, and injection-site tolerability.

Is a Fuzeon excipient patent likely to provide strong exclusivity?

A patent covering only a known excipient is unlikely to provide strong protection. Stronger claims would connect the excipient system to a defined technical result, such as improved stability, lower aggregation, reduced injection reactions, or a specific delivery device.

Does Fuzeon qualify for biosimilar competition?

Fuzeon is not the typical subject of a U.S. biosimilar application. Enfuvirtide is a synthetic peptide, so a generic, hybrid, or other follow-on pathway is more relevant than a monoclonal-antibody biosimilar pathway.

What is the best commercial strategy for a Fuzeon follow-on product?

The strongest strategy is an integrated product that reduces preparation frequency or complexity. A dual-chamber injection system or stable ready-to-use presentation would offer clearer differentiation than a formulation with only a different buffer or bulking agent.

References

1. Genentech USA, Inc. (2018). Fuzeon (enfuvirtide) prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2003). FDA approves Fuzeon, a new class of HIV drugs. FDA.

3. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.